restricting the use of Tasmar (tolcapone) due to reports of serious liver toxicity

The FDA and HPB are restricting the use of Tasmar (tolcapone) due to reports of serious liver toxicity...including three deaths.

Tasmar just came out last year. It's used to prolong the effect of levodopa in patients with advanced Parkinson's.

Now the FDA recommends limiting Tasmar to patients who can't take or don't respond to other Parkinson's drugs.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote